A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Recruiting

Phase 1

Phase 2

BMS-986340A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Sponsor:

Bristol-Myers Squibb

Code:

NCT04895709

Conditions

Cervical Cancer

Gastric/Gastroesophageal Junction Adenocarcinoma

Microsatellite Stable Colorectal Cancer

Non-Small-Cell Lung Cancer

Squamous Cell Carcinoma of Head and Neck

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BMS-986340

BMS-936558-01

Docetaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-16. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2025-01-06.